Ng Wang Yu Gary Acquires Shares in Niagen Bioscience

Ng Wang Yu Gary made a move in the stock market by buying 31,746 shares of Niagen Bioscience, Inc. (NasdaqCM: NAGE) on June 24, 2026. This insider transaction comes as the stock trades near $3.42, reflecting ongoing interest in the biotechnology firm.

Insider Buying and Selling at Niagen Bioscience, Inc.

Ng Wang Yu Gary wasn't alone in showing confidence in Niagen Bioscience. On the same day, several other insiders, including Jaksch Frank Jr, Cohen Ann, and Rubin Steven, also purchased 31,746 shares each. These transactions were not part of any pre-planned trading programs.

Other Institutional Activity in Niagen Bioscience

Institutional activity around Niagen Bioscience has been mixed. BlackRock, Inc. trimmed its holdings by 204,090 shares, bringing its total to 3,871,619 shares worth about $17.1 million, a 5% decrease. Meanwhile, SteelPeak Wealth, LLC opened a new position with 3,373,000 shares valued at approximately $14.9 million. Arrowstreet Capital, Limited Partnership increased its stake by 761,685 shares, now holding 2,378,437 shares worth $10.5 million, marking a 47.1% increase. Vanguard Capital Management LLC also initiated a new position with 2,149,277 shares, valued at about $9.5 million.

Niagen Bioscience, Inc. Stock Up 4.0%

Shares of Niagen Bioscience, Inc. traded near $3.42 on Saturday. The company has a market cap of $272.4 million and a P/E ratio of 16.3, indicating its profitability. With a beta of 2.06, the stock is quite volatile. Over the past year, it has ranged from a low of $3.29 to a high of $14.69. The 50-day moving average stands at $3.99, while the 200-day moving average is $5.83.

Recent Earnings

Niagen Bioscience reported revenue of $130.4 million, with a modest growth of 3.3%. The company's net margin is 14.3%, and it boasts a return on equity of 27.1%. Investors can look forward to the next earnings report on August 5, 2026.

Analysts Set New Price Targets

Analysts remain optimistic about Niagen Bioscience. On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating with an $11.00 price target. Canaccord Genuity also maintained a 'buy' rating with a $10.00 target on May 5, 2026. Overall, the consensus target price is $12.60 from five analyst opinions.

About Niagen Bioscience

Niagen Bioscience, Inc., headquartered in Los Angeles, California, operates in the healthcare sector, specializing in biotechnology. The company focuses on developing healthy aging products, including dietary supplements and pharmaceutical-grade ingredients. With 117 employees, Niagen Bioscience markets its flagship ingredient, nicotinamide riboside, under the brand name NIAGEN, and distributes products through its platform TRUNIAGEN.com, Amazon, and other marketplaces.

Bottom Line

Ng Wang Yu Gary's recent purchase of Niagen Bioscience shares underscores continued insider interest in the company. With a volatile stock trading near its 52-week low, investors are watching closely for the company's next earnings report and analyst updates. As always, it's crucial to remember that insider transactions provide a backward-looking glimpse into potential confidence in the company's future.